Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
120
resultados
Última actualización
21/11/2025 [07:19:00]
Resultados 75 a 100 de 120
Resumen de: CN120446472A
The invention relates to the technical field of biology, discloses a method for predicting and evaluating inflammatory bowel disease fibrosis through prostacyclin detection, and particularly relates to a serological biomarker for predicting and evaluating inflammatory bowel disease fibrosis and application of the serological biomarker. According to the method for predicting and evaluating inflammatory bowel disease fibrosis through prostacyclin detection, as a biomarker of inflammatory bowel disease fibrosis, PGI2 in serum can be used for preparing reagents and/or drugs for auxiliary diagnosis, curative effect evaluation and relapse monitoring of inflammatory bowel disease fibrosis, the effect is remarkable, and the specificity is good. The reagent is preferably an ELISA diagnostic kit. The invention also discloses a method for predicting and evaluating the fibrosis truncation value of the inflammatory bowel disease by using the biomarker and a method for predicting and evaluating the fibrosis truncation value of the inflammatory bowel disease by using the biomarker.
Resumen de: JP2024015204A
To provide peptides, compositions and methods for treating gastrointestinal disorders.SOLUTION: The invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.SELECTED DRAWING: None
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: US2025249050A1
The invention relates to core components from five strains of independently isolated, identified and patent-deposited probiotics and fermentation metabolites thereof (postbiotics), as well as their use as a protector in alleviating dextran sulfate sodium (DSS) induced-colitis in mice. Further disclosed the mechanism of the probiotics and fermentation metabolites thereof (postbiotics) to alleviate colitis in mice.
Resumen de: WO2025163643A1
The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.
Resumen de: AU2024213250A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Resumen de: CN116514983A
The invention relates to the technical field of biological pharmacy, in particular to a DR3 extracellular domain targeting nano antibody and application thereof. The method comprises the following steps: immunizing alpaca by using a DR3 extracellular domain of an insect expression system, separating peripheral blood lymphocytes, carrying out total RNA extraction, carrying out reverse transcription, amplifying a nano antibody sequence, and finally separating to obtain three nano antibodies which are respectively named A2, A6 and H10. The three nano antibodies have different antigen complementarity determining regions, SPR results show that the three nano antibodies all show high-affinity binding with human DR3 extracellular domains, and the nano antibodies provided by the invention are expected to provide experimental factual basis for treatment thinking of DR3-related diseases.
Resumen de: CN120392795A
The invention discloses application of a natural small molecule K252d in preparation of a medicine for treating inflammatory bowel disease and a preparation method of the medicine, and belongs to the field of biological medicine. K252d can remarkably promote mutual combination of MDM2-FOXP3, improve expression of FOXP3, promote differentiation of iTreg and enhance stability of FOXP3 and a Treg cell inhibition function, so that the effect of treating the inflammatory bowel disease is achieved. Compared with other treatment schemes in the prior art, the target enhancement path provided by the invention has the advantages that the off-target effect is remarkably reduced, and the toxic and side effects are reduced.
Resumen de: US2025243546A1
The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.
Resumen de: WO2025160484A1
Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.
Resumen de: US2025244340A1
The present disclosure contemplates detecting and treating a pathological condition, such as intestinal ischemia such as acute mesenteric ischemia, necrotizing enterocolitis, inflammatory bowel disease, and bowel graft rejection in a subject's intestinal tract. The methodology comprises obtaining a sample from the subject; detecting whether an analyte such as Villin-1, α-glutathione S-transferase, or intestinal fatty acid binding protein (I-FABP) is present in the sample by contacting the sample with an anti-analyte antibody and detecting binding between analyte and the antibody; and diagnosing the subject with the condition when, for example, the presence of analyte in the sample is detected and exceeds the level of analyte in a healthy control sample. A superparamagnetic bead includes an anti-Villin-1 antibody; an anti-α-glutathione S-transferase antibody, or an anti-intestinal-fatty acid binding protein (I-FABP) antibody. A superparamagnetic bead comprising a surface coating that binds Villin-1, α-glutathione S-transferase, or intestinal-fatty acid binding protein (I-FABP).
Resumen de: US2025244312A1
Some embodiments described herein relate to a method of screening candidate therapeutics for gastrointestinal diseases, including inflammatory bowel diseases, ulcerative colitis, and Crohn's Disease, using an ex vivo biopsy high throughput platform. Some embodiments relate to a high-throughput method of screening an ex vivo biopsy for chromatin modifications associated with an gastrointestinal disease. Some embodiments relate to a multi-omic method of screening candidate therapeutics for treatment of gastrointestinal diseases, including inflammatory bowel diseases, ulcerative colitis, and Crohn's Disease.
Resumen de: US2025243548A1
Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.
Resumen de: US2022002805A1
Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.
Resumen de: CN120381239A
According to the borborygmus recognition method and device, the electronic equipment and the storage medium, the borborygmus signal is acquired, the signal is recognized based on the preset borborygmus recognition model, the borborygmus characteristics can be efficiently and accurately analyzed, and therefore a scientific basis is provided for evaluation of the activity range and the lesion range of colitis diseases. According to the method, the diagnostic efficiency and accuracy are improved, through non-invasive borborygmus signal analysis, complexity of traditional endoscopy and discomfort of a patient are avoided, and meanwhile the diagnostic accuracy is improved; and secondly, dynamic monitoring of disease activity is realized, the activity and lesion range of colitis can be evaluated in real time by continuously collecting and identifying borborygmus signals, and dynamic illness state data support is provided for doctors.
Resumen de: CN120369944A
The invention discloses a new target for predicting the curative effect of a PD-1 antibody on tumor and colitis, and belongs to the technical field of biomedicine. Based on experiments, the WD6305 is used independently to promote tumor growth, and the tumor growth speed when the WD6305 is combined with the PD-1 antibody is slower than that when the PD-1 antibody is used independently, so that the WD6305 and the PD-1 antibody have potential application value in preparation of the medicine for treating the tumor, and the application prospect is broad. Meanwhile, experiments show that METTL14 is a new target for predicting the curative effect of the PD-1 antibody on tumor and colitis.
Resumen de: CN116514983A
The invention relates to the technical field of biological pharmacy, in particular to a DR3 extracellular domain targeting nano antibody and application thereof. The method comprises the following steps: immunizing alpaca by using a DR3 extracellular domain of an insect expression system, separating peripheral blood lymphocytes, carrying out total RNA extraction, carrying out reverse transcription, amplifying a nano antibody sequence, and finally separating to obtain three nano antibodies which are respectively named A2, A6 and H10. The three nano antibodies have different antigen complementarity determining regions, SPR results show that the three nano antibodies all show high-affinity binding with human DR3 extracellular domains, and the nano antibodies provided by the invention are expected to provide experimental factual basis for treatment thinking of DR3-related diseases.
Resumen de: CN120369664A
The invention belongs to the field of biological medicines, and particularly discloses an identification method of honeysuckle flower polysaccharide and application of the honeysuckle flower polysaccharide in preparation of medicines for preventing or treating inflammatory bowel diseases. A DSS solution is used for inducing a mouse inflammatory bowel disease model, honeysuckle polysaccharide FLP is used for gavage treatment, and mouse weight, disease activity indexes, colorectal tissue pathological structures, spleen pathological structures, HE staining, intestinal microbial structures, intestinal metabolite spectrums and the like are detected and analyzed. Results show that the honeysuckle flower polysaccharide can delay inflammatory bowel diseases of model animals in an oral administration manner, and has the characteristics of high targeting property, convenience in administration and the like. Good application prospects are realized in the aspect of treating the inflammatory bowel disease.
Resumen de: CN120375071A
The invention relates to the field of medical image processing, and discloses a Crohn disease intestinal stenosis type identification method based on radiomics and deep learning, which comprises the following steps: marking a region of interest of an intestinal stenosis section through standardized ultrasonic gray-scale image acquisition, and extracting radiomics features and deep learning features; constructing a classification model based on image omics by using a random forest algorithm, and extracting deep features and constructing a classification model by using a ResNet50 deep learning network; in order to further improve the classification performance, in combination with the results of the radiomics model and the deep learning model, multi-modal classification is realized through weighted fusion; the classification result is used for distinguishing inflammatory stenosis and fibrous stenosis of the intestinal tract of the Crohn's disease. According to the method, the dependence of traditional ultrasonic diagnosis on experience of operators is overcome, the diagnosis consistency and accuracy are remarkably improved, and reliable support is provided for non-invasive accurate diagnosis of the Crohn disease intestinal stenosis type.
Resumen de: WO2025152918A1
Provided in the present invention are humanized anti-human CD132 monoclonal antibodies and the use thereof. The present invention performs humanized transformation on the basis of monoclonal chimeras 2D4 and 5H10, so as to obtain high-affinity humanized monoclonal antibodies h2D4H4K12 and h5H10H6K4 targeting the human CD132 by means of screening; therefore, without attenuating the antibody activity, the immunogenicity of parental chimeras is reduced, thus reducing the possible risk that medicated patients may generate immune responses on the antibodies. The monoclonal antibodies can be used for prevention, neutralization or treatment of autoimmune diseases related to IL-4, IL-7, IL-9, IL-15 and/or IL-21 cytokines, e.g. systemic lupus erythematosus, rheumatoid arthritis, vitiligo, psoriasis, alopecia areata, inflammatory bowel disease, systemic sclerosis, graft-versus-host disease and aplastic anemia.
Resumen de: WO2025155794A1
The present inventive concept provides a subject's fecal protein bioprofile and methods for establishing the same. Also provided are methods of determining a subject's risk for developing an inflammatory disorder, a neurological disorder, a neurodegenerative disorder, or a disorder associated with aging or monitoring the same. The inventive concept further provides kits for use in the methods described herein.
Resumen de: WO2025155566A1
An MIS beveled driver and methods are provided for implanting beveled IBS bone compression and fully threaded screws to encourage bone fusion. The driver includes an elongated driver shaft extending from a shaped distal end to a proximal handle, a beveled sleeve having an angled distal-most surface adjacent to the shaped distal end that couples with the bone screw, and beveled marks on the driver shaft to indicate an orientation of the sleeve. The sleeve is affixed to the driver shaft such that the angle of the distal-most surface remains aligned with the beveled marks. The sleeve ensures that the bone screw only assembles with the driver in an orientation that enables aligning a proximal head portion of the bone screw to be flush with the surrounding bone surface. The sleeve includes a radio marker to enable observation of the bone screw by way of fluoroscopy.
Resumen de: US2025237665A1
A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohn's disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohn's disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: US2025237648A1
Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.
Nº publicación: JP2025523610A 23/07/2025
Solicitante:
ノルディックバイオサイエンスエー／エス
Resumen de: CN119546632A
The present invention relates to a sandwich immunoassay for determining cross-linked collagen type V in a biological sample, and its use in identifying patients suffering from conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing a sandwich immunoassay.
BOPI
Sede Electrónica
